Donafenib in Chinese patients with advanced hepatocellular carcinoma (HCC): Really a new standard of care, or should we change paradigm for drug development in HCC?

Donafenib in Chinese patients with advanced hepatocellular carcinoma (HCC): Really a new standard of care, or should we change paradigm for drug development in HCC?

Not available.

Bibliographic Details
Main Authors: Francesca Negri, Camillo Porta
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-09-01
Series:Oncology Reviews
Subjects:
Donafenib
sorafenib
hepatocellular carcinoma
Chinese patients
patients’ selection.
Online Access:https://www.oncologyreviews.org/site/article/view/564

Similar Items

Similar Items